30 closest matches · ranked by relevance
Nasopharyngeal Carcinoma · Adverse Effect of Radiation Therapy · Brain Necrosis
Primary: Number of Participants With a Treatment Response — 38; 17 Participants
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
Brain Metastasis
Primary: Number of Participants With Symptomatic Radiation Necrosis — 1 Participants
Pancreatic Fistulae
Primary: Decreased Secretions — 1 participants
Radiation Necrosis
Primary: Change in Radiation Necrosis and Cerebral Edema After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) — 86.8; 38.6; 32.6; 14.5 cm^3 — p=0.012
Recurrent Melanoma
Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR
Solid Tumor Spine Metastases
Primary: Number of Participants With Radiographic Recurrence at 12 Months — 3 Participants
Thyroid Cancer
Primary: Percentage of Participants With Local-regional Progression-free Survival — 15.2 percentage of all participants
Benign Meningioma
Primary: Progression Free Survival — 91; 91; 86; 81 percentage of participants surviving — p=0.234
Metastatic Malignant Neoplasm to Brain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Tolerated Dose (MTD) of Hypofractionated Radiosurgery Defined as the Highest Dose Level Where a Grade 3 or Greater With an Attribution Score of ≥ 3 Develops in ≤…
Melanoma · Brain Metastases
Primary: 1-year Survival Rate — 31.8 Percentage of patients alive at 1 year
Squamous Cell Carcinoma of the Head and Neck
Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants
Metastatic Colorectal Cancer
Primary: Disease Stabilisation Rate — 0 Participants
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients
Recurrent Glioblastoma
Primary: Number of Participants to Complete Model Adapted Radiations Fractionation Scheduled — 14 Participants
Non-melanoma Skin Cancer
Primary: Cure Rate — 751 lesions
Brain Cancer
Primary: Number of Participants Who Received PET/CT and MRI Perfusion Studies — 53; 95 Participants
Head and Neck Cancer
Primary: Duration of Local Control — 4.6 number of months to local failure
Metastatic Epidural Spinal Cord Compression
Primary: Number of Participants Showing Improvement or no Further Progression of Motor Deficits at 1 Month Following Radiotherapy — 68; 69 Participants
Liver Cancer
Primary: The Safety of Hypofractionated Stereotactic Radiotherapy in Patients With Advanced Hepatocellular Carcinoma — 0; 0; 1; 3 Participants
Acetabular Fracture · Heterotopic Ossification
Primary: Number of Participants With Severe HO Formation — 3; 9 Participants
Breast Cancer
Primary: Ipsilateral Breast Tumor Recurrence Rates — 0; 0 percentage of participants
Brain Cancer · Neoplasm Metastasis · Cancer of Brain and Nervous System
Primary: Stereotactic Radiosurgery (SRS) Maximum-tolerated Dose (MTD) — 0; 0; 0; 0 Dose-limited toxicity (DLT) events
Breast Cancer
Primary: Local Recurrence Rate — 0 Participants
Cognitive/Functional Effects · Metastatic Cancer · Neurotoxicity
Primary: Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT — 3.0; 3.7 Months — p=<0.0001
Radiation Toxicity
Primary: Tissue Oxygenation — 62.5 mmHg — p=0.5
Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1; 2 Participants
Lung Cancer
Primary: Incidence of Chronic Neurotoxicity — 60; 85; 89 percentage of participants
Malignant Glioma
Primary: Central Nervous System (CNS) Toxicity — 1 participants
Head and Neck Cancer
Primary: Incidence of Treatment Related Adverse Events — 4; 2; 4; 1 Participants